Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

326.65USD
2:56pm EST
Change (% chg)

$-1.29 (-0.39%)
Prev Close
$327.94
Open
$329.67
Day's High
$330.42
Day's Low
$324.54
Volume
497,423
Avg. Vol
1,272,779
52-wk High
$348.84
52-wk Low
$244.28

Latest Key Developments (Source: Significant Developments)

Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock
Thursday, 30 Nov 2017 07:40am EST 

Nov 30 (Reuters) - Biogen Inc ::SARISSA CAPITAL MANAGEMENT'S ALEXANDER​ ‍DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING.  Full Article

Biogen appoints Jeff Capello as executive vice president and chief financial officer
Tuesday, 21 Nov 2017 07:30am EST 

Nov 21 (Reuters) - Biogen Inc ::Appoints Jeff Capello as executive vice president and chief financial officer.Says Capello's appointment as CFO effective as of Dec 11, 2017​.  Full Article

Acorda announces royalty monetization transactions for $53 mln
Friday, 17 Nov 2017 07:02am EST 

Nov 17 (Reuters) - Acorda Therapeutics Inc :Acorda announces royalty monetization transactions for $53 million.Acorda Therapeutics - A $40 million royalty monetization with healthcare royalty partners and a $13 million royalty monetization with H. Lundbeck A/S​.Acorda Therapeutics Inc - ‍ In return for payment to Acorda, HCR obtains right to receive royalty revenue on Fampyra payable by Biogen.Acorda - ‍H. Lundbeck, Acorda amended license agreement for selincro to eliminate future royalty, milestone obligations on sale of Selincro outside U.S..Acorda Therapeutics Inc - Transaction does not include potential future milestones to be paid by Biogen​.  Full Article

Biogen presents new data from long-term extension of phase 1B study
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Biogen Inc ::Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab.Biogen Inc - ‍as of October 2017, Biogen and Eisai entered into a global collaboration agreement to jointly develop and commercialize aducanumab​.Biogen Inc - ‍results are consistent with previously reported analyses from phase 1B study​.  Full Article

Biogen Q3 earnings per share $5.79
Tuesday, 24 Oct 2017 06:59am EDT 

Oct 24 (Reuters) - Biogen Inc ::Biogen reports quarterly revenues of $3.1 billion.Q3 revenue $3.1 billion versus I/B/E/S view $3.04 billion.Biogen Inc - ‍company restructures collaboration arrangements with eisai and neurimmune to improve long-term value of aducanumab​.Biogen qtrly ‍ non-gaap diluted eps $ 6.31​.Q3 earnings per share $5.79.Biogen - qtrly tecfidera revenue of ‍$ 1,070​ million versus. $1,034 million.Biogen - qtrly plegridy revenue of $‍​124 million versus $128 million last year.Biogen - qtrly avonex revenue of $‍538​ million versus. $580 million.Biogen - qtrly tysabri revenue of $‍​469 million versus $515 million last year.Biogen - qtrly spinraza revenue of $‍271​ million versus. $203 million in q2.Q3 earnings per share view $5.73 -- Thomson Reuters I/B/E/S.  Full Article

Biogen increases profit potential on investigational Alzheimer’S disease treatment
Tuesday, 24 Oct 2017 06:29am EDT 

Oct 24 (Reuters) - Biogen Inc :Biogen increases profit potential on investigational Alzheimer’S disease treatment Aducanumab through amended agreement with Neurimmune Holding AG.Makes a one-time $150 million payment to Neurimmune in exchange for a 15 percent reduction in previously negotiated royalty rates​.‍Biogen licensed worldwide rights to Aducanumab from Neurimmune in 2007​.‍Also has an option to further reduce royalty owed on potential commercial sales of Aducanumab by an additional 5 percent.Option to reduce royalty owed on potential sales of Aducanumab by 5 percent is in exchange for additional one-time $50 million payment to Neurimmune.  Full Article

Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab
Monday, 23 Oct 2017 07:15am EDT 

Oct 23 (Reuters) - Biogen Inc :Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab.Biogen Inc - ‍Eisai has exercised its option to jointly develop and commercialize aducanumab, with Biogen continuing as development lead​.Biogen Inc - Co, Eisai to co-promote co's multiple sclerosis treatments, avonex , tysabri, tecfidera in Japan to accounts that co does not call upon​.Biogen Inc - ‍Neither party is making any upfront payments associated with exercise of aducanumab option​.Biogen Inc - ‍Under terms of agreement co will receive 55 percent of potential profits in United States and 68.5 percent of potential profits in Europe​.Biogen Inc - ‍Eisai's, Biogen's respective milestone payments under original agreement for aducanumab and BAN2401, have been eliminated​.Biogen Inc - ‍ Companies will continue to jointly develop elenbecestat (e2609), a beta amyloid cleaving enzyme (bace) inhibitor, and BAN2401​.Biogen Inc - ‍Financial terms for elenbecestat and ban2401 remain unchanged, other than eliminated BAN2401 milestone payments​.Biogen - Co to continue to lead phase 3 development of aducanumab, remain solely responsible for development costs for aducanumab until April 2018​.Biogen Inc - ‍ Under terms of agreement Eisai will receive 80 percent of potential profits in Japan and Asia excluding China and South Korea​.  Full Article

IONIS PHARMACEUTICALS INITIATES IONIS-MAPT RX STUDY IN PATIENTS WITH ALZHEIMER'S DISEASE
Friday, 13 Oct 2017 07:00am EDT 

Oct 13 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS PHARMACEUTICALS INITIATES CLINICAL STUDY OF IONIS-MAPT RX IN PATIENTS WITH ALZHEIMER'S DISEASE.IONIS PHARMACEUTICALS INC - ‍IONIS EARNS $10 MILLION MILESTONE PAYMENT FROM BIOGEN​.  Full Article

Biogen appoints Sanjay Jariwala as SVP
Tuesday, 12 Sep 2017 07:30am EDT 

Sept 12 (Reuters) - Biogen Inc ::Biogen appoints Sanjay Jariwala as SVP, worldwide medical.  Full Article

Forward pharma says filing in U.S. Court to appeal PTAB decision​
Tuesday, 5 Sep 2017 05:00pm EDT 

Sept 5 (Reuters) - Biogen Inc :Forward pharma a/s says filing in a u.s. Court of opening brief for appeal of a ptab decision​.Forward pharma - ‍the ptab decision ended interference proceeding between forward's 11/576,871 patent application and an issued biogen patent​.Forward pharma - ‍after biogen files its responsive brief, currently due oct 16, 2017, forward is allowed a reply brief, currently due october 30, 2017​.Forward pharma a/s - ‍an oral argument is expected to be held before the federal circuit in late 2017 or early 2018​.  Full Article

BRIEF-Biogen Appoints Mark Hernon As SVP, Chief Information Officer

* BIOGEN APPOINTS MARK HERNON AS SVP, CHIEF INFORMATION OFFICER Source text for Eikon: Further company coverage: